Table 2.
Multivariable Cox Regression Analysis in Predicting Factors for Perianal Crohn’s Disease Relapse After Discontinuation of Infliximab
| Variable | Odds Ratio (95% CI) | P value |
|---|---|---|
| Gender | 0.077(0.005–1.16) | 0.064 |
| Disease location | ||
| L1-ileal | - | - |
| L2-ileocolonic | 0.115(0.003–5) | 0.261 |
| L3-colonic | 0.68(0.035–13.231) | 0.799 |
| L4-upper digestive tract | 0.307(0.012–7.766) | 0.474 |
| Disease phenotype | ||
| B1-non-penetrating non-stricturing | - | - |
| B2-stricturing | 0.55(0.176–1.711) | 0.302 |
| B3-penetrating | 4.324(1.269–14.73) | 0.019 |
| Complex fistula | 3.392(1.158–9.936) | 0.026 |
| IFX therapy discontinuation | 2.43(1.061–5.565) | 0.036 |
| Chemotherapy | 0.736(0.155–3.491) | 0.7 |
Abbreviation: IFX, infliximab.